MPLT (MapLight Therapeutics) Short Percentage of Float


MPLT MapLight Therapeutics Inc MPLT
14 GF Score
Price $37.11
! 4 Warning Signs
View Full Analysis

What is MapLight Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MPLT vs COAG, CAPR, NVAX: Short Percentage of Float Comparison

For the Biotechnology subindustry, MapLight Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MapLight Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MapLight Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where MapLight Therapeutics's Short Percentage of Float falls into.


MPLT
14GF Score
MapLight Therapeutics Inc MPLT
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MapLight Therapeutics Business Description

Address 800 Chesapeake Drive, Redwood City, CA, USA, 94063
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score

Get the complete analysis for MPLT

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.11
Price